“The Applicant evaluated the safety of lazertinib using Sprague-Dawley rats and Beagle dogs in GLP-compliant oral repeat-dose toxicology studies of up to 13-weeks duration.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Pivotal GLP studies
4-week and 13-week oral studies in rats and dogs
“The toxicological profile of lazertinib was assessed in pivotal repeat-dose oral 4-week and 13-week toxicity studies in SD rats and Beagle dogs.”